Atlas Trials

MoonLake Immunotherapeutics AG

10 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch MoonLake Immunotherapeutics AG

RecordFirmDate
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis (NCT07223138)MoonLake Immunotherapeutics AG2025-11-13
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa (NCT07007637)MoonLake Immunotherapeutics AG2025-06-27
An Open-label Study in Healthy Adults to Evaluate the Relative Bioequivalence of a Single-dose Administration of Sonelokimab Either by a Prefilled Syringe or an Autoinjector (NCT06994936)MoonLake Immunotherapeutics AG2025-06-05
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN) (NCT06768671)MoonLake Immunotherapeutics AG2024-12-30
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug (NCT06641076)MoonLake Immunotherapeutics AG2024-10-15
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response (NCT06641089)MoonLake Immunotherapeutics AG2024-10-15
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06411899)MoonLake Immunotherapeutics AG2024-05-15
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06411379)MoonLake Immunotherapeutics AG2024-05-14
Evaluation of Sonelokimab for the Treatment of Patients With Active Psoriatic Arthritis (NCT05640245)MoonLake Immunotherapeutics AG2022-12-13
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa (NCT05322473)MoonLake Immunotherapeutics AG2022-04-25

Track MoonLake Immunotherapeutics AG automatically

Every clearance here is in the API, with alerts when new ones post.